Timigutuzumab

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameTimigutuzumab
Drug Alias NameTrasGEXTrastuzuMab-GEXTrastuzumab glyco-optimised (Glycotope)GT-Mab-7.3-GEX
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalyAustriaGermany +[4] 
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlycotope Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlycotope Gmbh
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A